



May 22, 2015

The Corporate Relationship Department  
BSE Limited  
1 Floor, New Trading Ring  
Rotunda Building  
P J Towers, Dalal Street  
Fort, Mumbai - 400 001.

The Manager  
Listing Department  
National Stock Exchange of India Limited  
Exchange Plaza, C/1, G Block, Block G,  
Bandra - Kurla Complex  
Bandra (E)  
Mumbai - 400 051.

Dear Sirs,

Sub: Disclosure under SEBI (Prohibition of Insider Trading) Regulations, 2015  
Ref: Scrip Code BSE - 524552, NSE - SHASUNPHAR

In Compliance with the requirements of the SEBI (Prohibitions of Insider Trading) Regulations, 2015 ("the Regulations") we hereby inform you as follows:

1. Pursuant to the requirements of regulations 8(2) of the Regulations, the Company have formulated & published on its website [www.shasun.com](http://www.shasun.com) the "Code of Practices & Procedures for Fair Disclosure of Unpublished Price Sensitive Information," a copy of which is enclosed herewith for your record.
2. Pursuant to the requirements of regulation 9(1) of the regulations, the Company has formulated a Code of Internal procedures and Code of Conduct for Prevention of Insider Trading.

This is for your information and records.

Thanking you,

Yours Faithfully  
For Shasun Pharmaceuticals Ltd

  
S. MURALIKRISHNA  
COMPANY SECRETARY

Encl.: as above

SCGA/F-001/K/14

## Shasun Pharmaceuticals Limited

"Batra Centre"


No. 28, Sardar Patel Road, Post Box 2630, Guindy, Chennai-600 032, India.

Phone: 91-44-4344 6700 / 2220 7500, Fax: 91-44-2235 0278

email : shasun@shasun.com Website : www.shasun.com

TIN No. 33191540153, CST No.39072 / 06.09.76

CIN : L24117TN1976PLC007122



## **SHASUN PHARMACEUTICALS LIMITED**

### **CODE OF PRACTICES AND PROCEDURES FOR FAIR DISCLOSURE OF UNPUBLISHED PRICE SENSITIVE INFORMATION FOR ADHERING TO THE PRINCIPLES OF FAIR DISCLOSURE.**

**(As envisaged under Regulation 8(1) of the SEBI (Prohibition of Insider Trading) Regulations, 2015)**

1. The Company shall endeavor to make prompt public disclosure of all unpublished price sensitive information(s) that may impact price discovery, as soon as credible and concrete information comes into being, in order to make such information generally available.
2. The Company shall endeavor to make uniform and universal dissemination of unpublished price sensitive information to avoid selective disclosure.
3. The Company shall designate Compliance Officer to act as the Chief Investor Relations Officer to deal with dissemination of information and disclosure of unpublished price sensitive information.
4. The Company shall endeavor to make prompt dissemination of unpublished price sensitive information that gets disclosed selectively, inadvertently, or otherwise to make such information generally available.
5. The Company shall make appropriate and fair response to queries on news reports and requests for verification of market rumors by regulatory authorities.
6. The Company shall ensure that information shared with analysts and research personnel is not unpublished price sensitive information.
7. No communication shall be made by the Company at any analyst or investor of any Unpublished Price Sensitive Information or a part thereof at any such meetings with analysts or investor conferences. All information communicated at such meetings will be only such information that is available in public domain or otherwise disclosed on the website of the company or in transcripts or recordings of quarterly results call disclosed on the website of the company.
8. The Company shall endeavor to put in place a system to ensure handling of all unpublished price sensitive information on a need-to-know basis.

